Clinical Trials Logo

Hepatitis C, Chronic clinical trials

View clinical trials related to Hepatitis C, Chronic.

Filter by:

NCT ID: NCT01846455 Completed - Hepatic Impairment Clinical Trials

Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects

Start date: August 2012
Phase: Phase 4
Study type: Interventional

Pharmacokinetics of Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment and in HCV-Seropositive Subjects, and in Healthy Volunteers.

NCT ID: NCT01842451 Completed - Hepatitis C Clinical Trials

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C

Start date: June 2013
Phase: Phase 2
Study type: Interventional

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Treatment-Naïve Adult Subjects With Genotype 1 Chronic Hepatitis C

NCT ID: NCT01841775 Completed - Clinical trials for Hepatitis C, Chronic

Interferon α 2b Pharmacovigilance Study

Start date: May 2009
Phase: Phase 4
Study type: Interventional

Multicenter prospective follow-up of a not controlled chronic hepatitis C genotypes 2/3 patients cohort with treatment indication with interferon α 2b and ribavirin for 24 weeks, and the verification of sustained virological response at week 48. The eligibility criteria and outcome measures followed the Clinical Protocol and Therapeutic Guidelines for Chronic Viral Hepatitis C, published by the Ministry of Health: http://portal.saude.gov.br/portal/arquivos/pdf/pcdt_hepatite_c_2011_retificado.pdf

NCT ID: NCT01833533 Completed - Clinical trials for Chronic Hepatitis C Infection

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection

PEARL-IV
Start date: March 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and antiviral activity of ABT-450/ritonavir/ABT- 267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) with and without ribavirin (RBV) in patients with chronic hepatitis C virus genotype 1a (HCV GT1a) infection without cirrhosis.

NCT ID: NCT01830127 Completed - Clinical trials for Hepatitis C, Chronic

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

Start date: April 2013
Phase: Phase 2
Study type: Interventional

To assess the pharmacokenetic characteristics of 600 mg BID BI 207127 / 120 mg QD faldaprevir /ribavirin in a small number of GT1b HCV infected patients with mild hepatic impairment (CPA) (Arm 1) versus 400 mg BID BI 207127 / 120 mg QD faldaprevir /ribavirin in a small number of GT1b HCV infected patients with moderate hepatic impairment (CPB) (Arm 2).

NCT ID: NCT01826981 Completed - Chronic Hepatitis C Clinical Trials

Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

Start date: April 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the antiviral efficacy, safety, tolerability of combination therapy with sofosbuvir (SOF) containing regimens for the treatment of chronic hepatitis C virus (HCV) infection.

NCT ID: NCT01818856 Completed - HIV Infection Clinical Trials

Pharmacokinetic Interactions Between Telaprevir and Un-boosted Atazanavir

Start date: December 2012
Phase: Phase 1
Study type: Interventional

Hypothesis: the Telaprevir(TVR) plasma levels (750 mg q8h or 1125 mg/12h )will not be affected when co-administered with un-boosted Atazanavir (ATV) 200 mg q12h plus two analogues (NRTIs) in HCV/HIV-co-infected patients.

NCT ID: NCT01817985 Completed - Chronic Hepatitis C Clinical Trials

A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

Start date: March 2013
Phase: Phase 1
Study type: Interventional

This is a Phase 1 Open-Label, Parallel-Group, Single-Dose Study to evaluate the Pharmacokinetics of GS-5816 in subjects with normal hepatic function and moderate or severe hepatic impairment.

NCT ID: NCT01813552 Completed - Clinical trials for Chronic Hepatitis C Infection

To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006)

Start date: February 2013
Phase: Phase 1
Study type: Interventional

This study is designed to evaluate the potential for an effect of Ritonavir (Norvir®) or omeprazole (Prilosec®) on the pharmacokinetics of samatasvir and to assess the safety and tolerability of the study drugs when administered alone and in combination in healthy participants.

NCT ID: NCT01813513 Completed - Clinical trials for Chronic Hepatitis C Infection

Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004)

Start date: January 2013
Phase: Phase 1
Study type: Interventional

The purpose of this 3-part study is to evaluate the potential impact of simeprevir and food on pharmacokinetics (PK) of IDX719 in healthy participants. Part 1 will evaluate potential PK interactions between IDX719 and simeprevir. Part 2 will evaluate the effect of food on the PK of IDX719 in combination with simeprevir. Part 3 will evaluate the impact of high- versus low-fat meals on the PK of IDX719.